Clinical Trial Update: DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dalbavancin for Staphylococcus aureus bacteremia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia

Drugs mentioned

• Dalbavancin (dalbavancin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Staphylococcal Bacteraemia | Phase 2 | Status: COMPLETED | Results posted: 2024-10-22